OVERVIEW OF THE CASE AND ONGOING INVESTIGATION
STUEVE SIEGEL HANSON LLP is investigating King Pharmaceuticals, Inc. concerning its prescription drug Avinza CII (morphine sulfate extended-release capsules).
King Pharmaceuticals was recently informed by the Food and Drug Administration ("FDA") that the government agency believed that King Pharmaceuticals was falsely and/or misleadingly advertising Avinza. Avinza, a controlled substance under Schedule II of the Controlled Substances Act, is prescribed to treat moderate to severe chronic pain. The FDA has stated that some of the advertising for "Avinza is false or misleading in that it presents efficacy claims for Avinza but fails to communicate and minimizes risks associated with its use, fails to present the limitations to its approved indication, and presents unsubstantiated efficacy claims."
If you or a family member have been prescribed Avinza and would like to discuss your potential claim with an attorney, please contact Todd Hilton at 866-668-9241 or email him at hilton@stuevesiegel.com.
Why Stueve Siegel Hanson?
Stueve Siegel Hanson is a national litigation firm specializing in complex business litigation, securities litigation, and consumer class actions. We have obtained substantial results for our clients in all types of litigation around the country, and have collectively been honored with dozens of awards and designations, for both our trial successes, and case results.
